0001354457-24-000186.txt : 20240321
0001354457-24-000186.hdr.sgml : 20240321
20240321142110
ACCESSION NUMBER: 0001354457-24-000186
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20240321
DATE AS OF CHANGE: 20240321
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nemaura Medical Inc.
CENTRAL INDEX KEY: 0001602078
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 465027260
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38355
BUSINESS ADDRESS:
STREET 1: 57 WEST 57TH STREET
CITY: MANHATTAN
STATE: NY
ZIP: 10019
BUSINESS PHONE: 44-1509-222-912
MAIL ADDRESS:
STREET 1: 57 WEST 57TH STREET
CITY: MANHATTAN
STATE: NY
ZIP: 10019
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
ORGANIZATION NAME:
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001602078
Nemaura Medical Inc.
001-38355
Advanced Technology Innovation Centre
5 Oakwood Drive Loughborough
Leicestershire
X0
UNITED KINGDOM
LE11 3AQ
44 1509 222912
Common stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2024-03-20
EX-99.25
2
nmrddelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, March 21, 2024,
Nemaura Medical Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of Nemaura Medical Inc., effective at the
opening of the trading session on April 1, 2024.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rule 5550(a)(2). The Company was notified
of the Staff determination on October 3, 2023. On October 4, 2023, the
Company received an additional delist determination for its failure to
meet the requirement in Listing Rule 5550(a)(2).
On October 10, 2023, the Company exercised its right to appeal the Staff
determination to the Listing Qualifications Hearings Panel (Panel)
pursuant to Listing Rule 5815.
On December 12, 2023, upon review of the information provided by the Company,
the Panel determined to grant the Company request to remain listed in
the Exchange subject to a series of milestones.
Based on the Company failure to meet the terms of the exception, on
January 3, 2024, the Panel issued a final decision denying the Company
continued listing and notified the Company that trading in the Company
securities would be suspended on January 5, 2024.
The Company did not appeal the Panel decision to the Nasdaq Listing and
Hearing Review Council (Council) and the Council did not call the matter
for review. The Staff determination to delist the Company became final on
February 20, 2024.